Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89%
PAXLOVID™, significantly reduced hospitalization and death, based on an interim analysis of the Phase 2/3 EPIC-HR.
Pfizer & The MPP Sign Licensing Agreement for COVID-19 Oral Antiviral Treatment Candidate to Expand Access
Agreement builds on Pfizer’s comprehensive strategy to work toward equitable access to COVID-19 vaccines and treatments for all people.
Tens of thousands of shots will be carried to the ‘real last mile’ as part of Covax program to improve global distribution.